Maria Francesca Astorino

Dr. Maria Francesca Astorino

University of Messina, Messina, Sicilia, Italy
orcid

Research Focus & Metrics

Representative Publications

View All Publications
14 July 2025 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Open access
Maria Francesca AstorinoMaria Francesca Astorino
Maria Francesca Astorino
MCMarco Calabrò
Marco Calabrò
CICarmenrita Infortuna
Carmenrita Infortuna
MMMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
SBSilvana Briuglia
Silvana Briuglia
CCConcetta Crisafulli
Concetta Crisafulli
Mental disorders are a significant global public health concern, affecting nearly one in eight individuals worldwide. This review investigates the multifaceted etiology of mental disorders—specifically major depressive disorder (MDD), schizophrenia (SCZ), and bipolar disorder (BD)—through genetic, neurobiological, and environmental perspectives, with a particular emphasis on the role of trace elements (TrEs). TrEs such as zinc, magnesium, copper, iron, and selenium are essential micronutrients that influence several central nervous system functions, including enzymatic activity, neurotransmitter synthesis, and synaptic plasticity. Both deficiencies and excesses of these elements have been linked to psychiatric disorders. This study explores the associations between TrEs, psychiatric symptoms, and biological pathways due to the Research Domain Criteria (RDoC) framework. We discuss clinical evidence and genetic studies to evaluate possible correlations between TrEs and key RDoC endophenotypes. By elucidating these connections, this review focuses on the potential and current limitations of TrEs in mental health.

Verified
Journal Article
Open access
PDF file
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
IRIvana Raffaele
Ivana Raffaele
AFAlessia Floramo
Alessia Floramo
VAVeronica Argento
Veronica Argento
DDDeborah Stefania Donato
Deborah Stefania Donato
IAIvan Anchesi
Ivan Anchesi
Hericium erinaceus (H. erinaceus), a medicinal mushroom, is a source of bioactive compounds with demonstrated neuroprotective potential. This activity is primarily attributed to two distinct classes of compounds: erinacines from the mycelium, which potently induce the synthesis of neurotrophins, protein growth factors essential for neuronal survival and health, and hericenones from the fruiting body, which subsequently appear to enhance or potentiate neurotrophin-activated signaling pathways. Preclinical evidence substantiates their ability to enhance neurotrophin levels, particularly Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), and activate their cognate Trk receptors. Activation of these pathways, including PI3K/AKT/mTOR and MAPK/ERK, converges on transcription factors such as CREB, promoting neuronal survival, neurite outgrowth, and synaptic plasticity. However, the precise molecular mechanisms linking these small molecules to the complex orchestration of neurotrophic gene expression remain incompletely defined. This review synthesizes current knowledge of the neurotrophic pharmacology of H. erinaceus bioactives and proposes a novel framework suggesting that non-coding RNAs (ncRNAs) play a key regulatory role. We hypothesize that hericenones and erinacines modulate key transcriptional hubs, such as CREB, Nrf2, and NF-κB, which in turn regulate the expression of specific ncRNAs (e.g., miR-132, miR-146a) known to control neurogenesis, synaptogenesis, oxidative stress, and neuroinflammation. This ncRNA-mediated mechanism may represent an un-explored axis that explains the pleiotropic neuroprotective effects of these compounds. We critically appraise the existing preclinical evidence, identify significant methodological limitations and translational gaps, and propose a structured research roadmap to test these ncRNA-centric hypotheses, aiming to accelerate the rational development of H. erinaceus-derived compounds for neurodegenerative diseases.

26 November 2025 in Cells
Verified
Journal Article
Open access
PDF file
IAIvan Anchesi
Ivan Anchesi
Maria Francesca AstorinoMaria Francesca Astorino
Maria Francesca Astorino
IRIvana Raffaele
Ivana Raffaele
DDDeborah Stefania Donato
Deborah Stefania Donato
SSSerena Silvestro
Serena Silvestro
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
Multiple Sclerosis (MS) therapies effectively modulate peripheral immune responses but largely fail to promote neural repair within the central nervous system. This review evaluates whether psychedelic compounds (PSYs), via 5-HT2A activation, can fill a critical therapeutic gap: the need for agents that simultaneously suppress neuroinflammation and promote regeneration. We dissect the evidence suggesting PSYs can reprogram the neuroimmune milieu by downregulating key pro-inflammatory cytokines (e.g., TNF-α, IL-6) in glial cells while concurrently upregulating crucial neurotrophic factors (e.g., BDNF) that promote synaptic plasticity and oligodendrocyte support. However, we argue that the current evidence, largely derived from non-specific inflammation models, is insufficient to predict clinical efficacy in an autoimmune disease like MS. We critically analyze the significant translational barriers—from cardiovascular and psychiatric risks to profound legal and ethical challenges—that temper the immediate clinical promise. Finally, we propose a forward-looking perspective, suggesting that the true value of PSYs may lie not in their direct clinical use, but in uncovering novel therapeutic pathways. The emergence of non-hallucinogenic, functionally selective 5-HT2A agonists, inspired by psychedelic pharmacology, represents a more viable strategy to harness these mechanisms for MS therapy, demanding rigorous preclinical validation in disease-relevant models.

Verified
Journal Article
Open access
PDF file
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
IRIvana Raffaele
Ivana Raffaele
AFAlessia Floramo
Alessia Floramo
VAVeronica Argento
Veronica Argento
Maria Francesca AstorinoMaria Francesca Astorino
Maria Francesca Astorino
IAIvan Anchesi
Ivan Anchesi
This narrative review proposes the ‘Brain Health Triad’ as a novel integrative framework for neurorehabilitation and cognitive enhancement, built upon three interdependent biological pillars: neurostimulation, neurotrophy, and neuroprotection. We illustrate how the synergistic interplay between a ‘core triad’ composed of Hericium erinaceus, Bacopa monnieri, and L-Theanine targets these pillars with high specificity. Hericium erinaceus fosters neurotrophy by inducing Nerve Growth Factor (NGF) and Brain-derived neurotrophic factor (BDNF) synthesis through erinacines and hericenones; Bacopa monnieri complements this by enhancing neurostimulation and synaptic plasticity via bacosides; and L-Theanine regulates neurotransmitter balance and alpha-wave activity to stabilize the neural signaling environment. This core architecture is further reinforced by adjunctive nootropic clusters—including withanolides, ginkgolides, citicoline, cordycepin, macamides, and fulvic acid—which provide essential support for mitochondrial resilience and the mitigation of amyloid-β and tau toxicities. By synthesizing molecular evidence from the BDNF/TrkB/CREB signaling axis and the Nrf2/NF-κB homeostatic switch, we demonstrate that this multi-target strategy offers a more robust path to neuronal resilience than traditional single-target approaches. We conclude that this integrated model provides a solid framework for future clinical applications in the management of age-related cognitive decline and neurodegenerative diseases.

Verified
Journal Article
Open access
PDF file
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
IAIvan Anchesi
Ivan Anchesi
IRIvana Raffaele
Ivana Raffaele
Maria Francesca AstorinoMaria Francesca Astorino
Maria Francesca Astorino
AMAurelio Minuti
Aurelio Minuti
CCConcetta Crisafulli
Concetta Crisafulli
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) plaque deposition, neurofibrillary tau tangles, synaptic dysfunction, and progressive cognitive decline. AD is increasingly recognized as a condition in which chronic neuroinflammation actively shifts amyloid precursor protein (APP) processing toward the amyloidogenic pathway, driving Aβ production and accumulation rather than merely accompanying amyloid deposition. In this review, we examine the molecular cross-talk between inflammatory signalling and secretase regulation, highlighting how pro-inflammatory mediators promote amyloidogenic processing and contribute to downstream synaptic dysfunction. We discuss the major pathways linking glial activation to aberrant APP cleavage, including STAT3-dependent BACE1 upregulation, immune-mediated modulation of γ-secretase through IFITM3, and activation of the C/EBPβ/δ-secretase axis, which connects inflammatory stress to both amyloid and tau pathology. We further address the contribution of epigenetic mechanisms, particularly microRNA-mediated derepression of BACE1 and suppression of ADAM10, as well as SIRT3-related impairment of Aβ clearance. These interconnected processes establish a feed-forward pathogenic network in which neuroinflammation amplifies secretase imbalance, amyloidogenesis, and synaptic vulnerability. Finally, we discuss emerging multi-target therapeutic strategies aimed at modulating inflammatory signalling, restoring non-amyloidogenic APP processing, and preserving proteostatic and synaptic resilience. Collectively, this framework supports the view that targeting the inflammatory control of secretase activity may represent a biologically relevant strategy for disease modification in AD.

Verified
Journal Article
Open access
PDF file
IAIvan Anchesi
Ivan Anchesi
IRIvana Raffaele
Ivana Raffaele
Maria Francesca AstorinoMaria Francesca Astorino
Maria Francesca Astorino
MLMaria Lui
Maria Lui
MCMarco Calabrò
Marco Calabrò
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
The clinical renaissance of psychedelic medicine has highlighted the therapeutic potential of rapid-acting neuroplastogens, or “psychoplastogens,” for psychiatric disorders. However, the widespread application of classical psychedelics—such as psilocybin and LSD—and the atypical dissociative ibogaine is severely limited by their hallucinogenic properties and, particularly in the case of ibogaine, life-threatening cardiotoxicity. Addressing these limitations, Tabernanthalog (TBG) has emerged as a frontrunner in the field. This non-hallucinogenic analog of ibogaine was rationally designed to eliminate interactions with the human ether-à-go-go-related gene (hERG, KCNH2) potassium channel, thereby mitigating cardiotoxic risks. While initially characterized for its anti-addictive and antidepressant-like properties, recent data from 2024–2025 have significantly expanded its therapeutic horizon. TBG demonstrates robust efficacy in preclinical models of neuropathic and visceral pain, as well as in the rescue of cognitive deficits associated with cancer-related cognitive impairment (CRCI). TBG has shown efficacy in reversing cognitive impairments induced directly by the presence of a tumor in preclinical models, rather than by chemotherapy-specific neurotoxicity. Crucially, emerging evidence suggests that TBG’s mechanism extends beyond simple 5-HT2A receptor agonism. New findings point to a multi-target profile involving the inhibition of nicotinic acetylcholine receptors (nAChRs), positive modulation of NMDA receptors, and functional crosstalk with mGlu2 receptors. Furthermore, TBG appears to induce structural neuroplasticity without the widespread induction of immediate early genes (IEGs) seen with classical hallucinogens, suggesting a decoupling of therapeutic rewiring from the subjective psychedelic experience. This review synthesizes current preclinical evidence to discuss TBG as a promising chemical scaffold for next-generation neurotherapeutics targeting the intersection of psychiatry and neurology.